Introduction
Primary amyloidosis is a disease that causes intractable nephrotic syndrome, with continuous progression to end-stage renal failure (ESRF) [1, 2] . Furthermore, it causes fatal cardiac conditions such as conduction disturbance and restrictive heart failure [3] . Although regular haemodialysis (HD) therapy has been attempted for ESRF in primary amyloidosis, a successful therapy has not been established yet [1, 3] . In this study of a patient with primary amyloidosis, we estimated the removal ratio of free light (L)-chain-a precursor of amyloid fibril-by various blood purification methods. In addition, we examined the usefulness of dimethyl sulfoxide (DMSO).
Case
A 58-year-old woman was admitted to Himeji National Hospital because of systemic oedema. Moderate proteinuria had been noted 6 months earlier. On admission, her blood pressure (BP) was 132u84 mmHg, controlled with a Ca 2q -antagonist, manidipine (10 mguday), and her pulse was regular at 76umin. Urinalysis demonstrated severe proteinuria at 5.1 guday and slight occult blood. Blood urea nitrogen and creatinine (Cr) were 31 and 1.7 mgudl, respectively, and the creatinine clearance rate (Ccr) was 48 mlumin. Total serum proteinualbumin was 4.2u2.0 gudl without M-protein or liver dysfunction. Abdominal ultrasonography demonstrated oedematous kidneys with sizes 11.4 3 5.1 (right) and 12.0 3 5.4 cm (left), but liver, gall bladder, spleen, and pancreas were normal. Cardiac examinations showed mild cardiomegaly [cardiothoracic ratio (CTR) 0.56] on chest X-ray, low voltage and 18 atrioventricular block on electrocardiogram (ECG), and 432 single ventricular premature contractions (VPCs) on 24-h Holter monitoring. Although left ventricular ejection fraction (LVEF) was normal at 69%, the intraventricular septum (IVS) and the left ventricular posterior wall (LVPW) were moderately to severely thickened at 17 and 16 mm without granular sparkling images on the ultrasonogram. Cardio-angiography showed intact coronary arteries. Biopsies of the kidney and the heart showed the accumulation of homogeneous materials that were positive to Congo red staining even after KMnO 4 treatment in the mesangial matrix and cardiac connective tissue. Electron microscopy demonstrated amyloid fibrils in both organs. Although Bence Jones protein (l type) was found in the urine sample, a level of plasma cells of 7% by myelogram was not compatible with multiple myeloma. The patient was prescribed with a diagnosis of primary amyloidosis. She was administered an immunosuppressant, mizoribine (150 mguday) and DMSO (5 guday).
Six months later, she was re-admitted because her renal function deteriorated-8.7 mgudl of serum Cr and 9.0 mlumin of Ccr. On the second admission, her BP was at 140u82 mmHg without use of antihypertensive drugs. CTR was up to 0.61 and she had mild bilateral pleural effusions. IVSuLVPW also were thickened to 20u16 mm and LVEF was decreased to 49%. The plasma level of free L-chain (l type) (puf L-chain) was 42 mgudl.
We first examined the change in the levels of puf L-chain (l type) using DMSO (12 g) i.v. injection in two trials. As shown in Figure 1 , there were no remarkable differences in the puf L-chain between samples obtained 0, 3, 6, 9, 12 and 24 h after DMSO injection.
Next, we measured and compared the removal ratios of puf L-chain (l type) with various methods such as HD with a cuprophane membrane dialyzer (HD-Cu) (ALF-100G, Nikkiso Co., Japan), HD with a polysulfone membrane dialyzer (HD-PS) (PS-1.6UW, Kawasumi Co., Japan), HD with a polyester-polymer alloy membrane dialyzer (HD-PEPA) (FLX-15GW, Nikkiso Co., Japan), haemodiafiltration (HDF) with the same PEPA dialyzer (HDF-PEPA) as utilized in HD (replacement liquid 6 l), haemofiltration (HF) with a PEPA dialyzer (HF-PEPA) (FLX-15GW) (replacement liquid 20 l) and direct plasma exchange (PE) (fresh frozen plasma 3.2 l). HD and HDF methods were all performed for 4 h with a fluid removal volume of 3 l, and HF was performed for 6 h without fluid removal. Blood samples were obtained from the pre-dialyzer line of blood circuit at the beginning and the end of each clearance method. The removal ratios of puf L-chain (l type) were as follows: 6.9% in HD-Cu, À3.3% in HD-PS, 13.1% in HD-PEPA, 26.0% in HDF-PEPA, 18.7% in HF-PEPA, and 25.3% in PE (Table 1) .
Based on these findings, HDF was performed three times a week with a PEPA dialyzer. The administration of DMSO and mizoribine was discontinued. Serum Cr concentration was maintained at 5.2-7.4 mgudl before HDF treatment. After the initiation of HDF, the puf L-chain remained at 25-30 mgudl throughout the course of treatment. Single VPC count decreased to 50-150u24 h. The thickness of IVSuLVPW remained at about 20u15 mm. However, LVEF gradually decreased to 47, 42 and 38% after 4, 12 and 24 months of HDF treatment, respectively. Systolic BP also decreased to 90, 70 and 50 mmHg after 10, 18 and 30 months, respectively. The patient died of restrictive heart failure with hypotension 37 months after the initiation of HDF. Permission for autopsy was denied.
Discussion
Primary amyloidosis is a fatal disease with the median survival of 1-2 years [1,2,4]. Arrhythmia and heart failure with hypotension due to restrictive cardiomyopathy are the most frequent causes of the death [3] . Blood purification therapies such as HD, peritoneal dialysis (PD) and plasmapheresis (PP), in addition to melphalan and prednisolone (MP) therapy and autologous stem-cell transplantation have been attempted, but effective treatment methods have not yet been established [1] [2] [3] [4] . In previous studies, DMSO was reported to be effective in improving clinical symptoms or renal function in patients with AA-and AL-type amyloidosis [5, 6] . We first examined the effect of DMSO in the removal of amyloid fibrils from tissues. Significant changes in the puf L-chain level were not observed after DMSO injections (200 mgukg body weight). We concluded that DMSO treatment might not reduce the accumulated amyloid fibrils in tissues, and stopped using DMSO.
We next measured the removal ratios of puf L-chain by various blood purification methods, and concluded that HDF with a PEPA dialyzer, as well as PE, was more effective than HD with a Cu, PA or PEPA dialyzer and HF with a PEPA dialyzer. Although a PS membrane is considered a high performance membrane (HPM) like PEPA, HD with a PS dialyzer did not remove free L-chain with a molecular weight of 23 000 in the monomeric form. This may be because the PS membrane has a pore size equal to or slightly larger than b2-microglobulin (molecular weight 11 500). We hypothesize that a PEPA membrane may have an uneven pore size that can remove free L-chain with molecular weights more than 23 000, and that the hydrophobic property of the PEPA membrane may favour the adsorption of free L-chain by molecular interaction.
It is uncertain if controlling the free L-chain level prolonged the survival of this patient. Her highest level of puf L-chain was 42 mgudl and the level was maintained at 25-30 mgudl after the initiation of HDF. Despite the rapid progression of renal and heart failures in the first 6 months of treatment with DMSO *Removal ratio (%)s(AÀB)uA 3 100. Fig. 1 . Timed changes in the levels of puf L-chain (l type) after DMSO (200 mgukg body weight) injection in two trials. There were no remarkable changes in the puf L-chain after either trial, measured between 3 and 24 h after the injections. and mizoribine, she survived 37 months after the initiation of HDF. Although long-lasting survivals of patients with diffuse primary amyloidosis have occasionally been described, Gertz et al. [2] in a study of 38 dialysis patients with primary amyloidosis reported that the median time from diagnosis to initiation of dialysis was 13.8 months and the median patient survival after the start of dialysis was 8.2 months. We suppose that the removal of puf L-chain contributed to prolonging the survival of this patient. As we have not shown a reduction in amyloid deposits in the heart, additional experience of HDF treatment would help understand the increased survival of our patient.
We did not attempt PD to remove free L-chain in this patient, because the patient did not consent to such treatment. In this regard, Gertz et al. [2] have reported that there was no survival difference between HD (ns27) and PD (ns10).
Finally, we regret that we did not treat her with a combination of intense chemotherapy including MP therapy, despite the rapid progression of her disease, and that we did not start HDF or PP earlier before she reached end-stage renal disease.
In summary, we present a patient with primary amyloidosis who survived 3 years and 1 month after the initiation of HDF with a PEPA dialyzer, a treatment that appears capable of removing substantial amounts of puf L-chain.
